Pseudomonas aeruginosa is a bacterial pathogen that can cause infections, particularly in individuals with weakened immune systems or underlying health conditions. Treatment of Pseudomonas aeruginosa infections typically involves antibiotics, and various pharmaceutical companies have developed drugs targeting this bacterium.
Latest Pseudomonas Aeruginosa Treatment Companies Update
Nov 2023: Kite, a Gilead Company, and Arcellx, Inc. announced that they have extended their current partnership, which was first disclosed in December 2022. In multiple myeloma, Kite has exercised its option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, which consists of SparX proteins that target BCMA and ARC-T cells. The firms have also extended their collaboration to cover lymphomas concerning Arcellx's CART-ddBCMA.  The deep and long-lasting responses seen in our CART-ddBCMA Phase 1 trial for multiple myeloma suggest that our unique synthetic binder, the D-Domain, can potentially open new avenues for developing CAR T treatments. They are eager to strengthen their partnership with Kite and increase their investment in our business as they exercise their rights under our ACLX-001 ARC-SparX program for multiple myeloma and continue making investments in our platform.
Nov 2023: Bristol-Myers Squibb bought lung cancer medication as part of its $4.1 billion acquisition of Turning Point Therapeutics last year and has received FDA approval. The medication, marketed under the brand name Augtyro, will face competition in the congested lung cancer treatment market from rival pharmaceutical companies Roche, Merck, and AstraZeneca and Opdivo, another cancer treatment from Bristol Myers.
Pseudomonas Aeruginosa Treatment Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)